Therefore, our findings characterize a novel post-transcriptional network that links cancer progression and immunomodulation within the tumor microenvironment through SORBS2-mediated transcript stabilization and could provide a theoretical rational for the potential clinical application value of such therapeutic targets for precision therapy of individuals with ovarian cancer. Here, SORBS2 is linked to cancer.